Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Operating Leases (2022 - 2025)

Historic Operating Leases for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $2.7 million.

  • Day One Biopharmaceuticals' Operating Leases rose 764.38% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 764.38%. This contributed to the annual value of $2.6 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Day One Biopharmaceuticals' Operating Leases stood at $2.7 million, which was up 764.38% from $2.8 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Operating Leases ranged from a high of $2.9 million in Q1 2025 and a low of $77000.0 during Q3 2023
  • Its 4-year average for Operating Leases is $1.4 million, with a median of $617000.0 in 2022.
  • Per our database at Business Quant, Day One Biopharmaceuticals' Operating Leases crashed by 8501.95% in 2023 and then skyrocketed by 319610.39% in 2024.
  • Over the past 4 years, Day One Biopharmaceuticals' Operating Leases (Quarter) stood at $408000.0 in 2022, then tumbled by 81.13% to $77000.0 in 2023, then skyrocketed by 3266.23% to $2.6 million in 2024, then grew by 5.4% to $2.7 million in 2025.
  • Its Operating Leases was $2.7 million in Q3 2025, compared to $2.8 million in Q2 2025 and $2.9 million in Q1 2025.